デフォルト表紙
市場調査レポート
商品コード
995632

尿失禁治療薬市場 - 市場規模、シェア、見通し、機会分析:2020年~2027年

Urinary Incontinence Treatment Drugs Market, by Incontinence Type, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 180 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.28円
尿失禁治療薬市場 - 市場規模、シェア、見通し、機会分析:2020年~2027年
出版日: 2021年02月18日
発行: Coherent Market Insights
ページ情報: 英文 180 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

尿失禁は、尿路にさまざまな異常が発生し、その結果として排尿が起こると考えられています。尿失禁治療薬市場は、尿失禁疾患の有病率の増加により、予測期間中に市場の成長を促進すると予想されます。

当レポートでは、世界の尿失禁治療薬市場について調査分析し、市場概要、市場規模と予測、セグメント別の市場分析、地域別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 調査目的と前提条件

第2章 市場概要

第3章 市場力学・規制・動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な発展
  • 規制シナリオ
  • 新規立ち上げと承認
  • パイプライン分析
  • PEST分析
  • 疫学

第4章 COVID-19の影響分析

  • 供給側分析
  • 需要側分析
  • 医療業界に対する影響

第5章 世界の尿失禁治療薬市場:失禁の種類別

  • イントロダクション
  • 切迫性尿失禁
  • 腹圧性尿失禁
  • 溢流性尿失禁
  • 混合性尿失禁
  • その他

第6章 世界の尿失禁治療薬市場:薬剤分類別

  • イントロダクション
  • 抗コリン作用薬/鎮痙薬
  • 骨格筋弛緩薬
  • 抗うつ薬
  • アルファ遮断薬
  • 局所エストロゲン
  • その他

第7章 世界の尿失禁治療薬市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 世界の尿失禁治療薬市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • ラテンアメリカ
  • アジア太平洋地域
  • 中東
  • アフリカ

第9章 競合情勢

  • 企業プロファイル
    • Johnson & Johnson
    • Pfizer Inc.
    • Astellas Pharma, Inc.
    • Allergan, Inc.
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc.
    • Sanofi SA

第10章 セクション

目次

Title:
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Urinary incontinence is considered to be the variety of abnormalities occurs in the urinary tract that results in to experiencing normal micturition. This leads to involuntary loss of bladder control. Approximately 40% of community-dwelling elderly and hospitalized patients are afflicted with this disorder and the remaining 60% of nursing home patients experience this disorder, and it is often the reason for their admittance. The causes of urinary incontinence are numerous and involves age-related changes in the bladder and urethra, including decline in outlet resistance in females and prostate enlargement in males.

In urinary incontinence, muscles around urethra do not work in the way they should, resulting in leak-out of urine. There are various types of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per health conditions such as urinary tract infection (UTI), constipation, and age group, as urinary incontinence is found more in geriatric population.

Market Dynamics

The urinary incontinence treatment drugs market is expected to drive the market growth during the forecast period, owing to increasing prevalence of urinary incontinence disease. For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.

Key features of the study:

  • This report provides in-depth analysis of the global urinary incontinence treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global urinary incontinence treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global urinary incontinence treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the urinary incontinence treatment drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
  • Global Urinary Incontinence Treatment Drugs Market, By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
  • Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Urinary Incontinence Treatment Drugs Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • ALPHA Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Incontinence Type:
  • Urge Incontinence
  • Stress Incontinence
  • Over-flow Incontinence
  • Mixed Incontinence
  • Other Type
    • By Drug Class:
  • Anticholinergic/Antispasmodic Agents
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
    • Johnson & Johnson
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
    • Pfizer Inc.
    • Astellas Pharma, Inc.
    • Allergan, Inc.
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc.
    • Sanofi S.A.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Incontinence Type
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • New Lunches and Approvals
  • Pipeline Analysis
  • PEST Analysis
  • Epidemiology

4. Impact Analysis of Covid-19

  • Supply side Analysis
  • Demand Side Analysis
  • Impact on Healthcare Industry

5. Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Urge Incontinence
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Stress Incontinence
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Over-flow Incontinence
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Mixed Incontinence
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Other Type
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Urinary Incontinence Treatment Drugs Market, By Drug Class, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Anticholinergic/Antispasmodic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Skeletal Muscle Relaxants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Alpha Blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Topical Estrogens
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Urinary Incontinence Treatment Drugs Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Latin America
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Asia Pacific
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Incontinence Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Company Profiles
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Astellas Pharma, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Allergan, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact